Financial Results
Anthem Biosciences Q1 FY27 Results: Revenue Declines 22.6% YoY, Maintains Strong 39.6% EBITDA Margin
NSE
Anthem
BSE
544449
Anthem Biosciences Limited reported its unaudited consolidated financial results for the quarter ended 30 June 2026. Revenue declined due to timing shifts in customer deliveries, while the company maintained healthy profitability with an EBITDA margin of 39.6% and PAT margin of 27.1%. Management indicated that demand remains strong and expects scheduled deliveries in the second half of the year to support business momentum.
PRICE-SENSITIVE TRIGGER
Event: Q1 FY27 Unaudited Consolidated Financial Results (Revised Press Release)
Type: Financial Results
Impact: Positive
Immediate Effect: Lower revenue and earnings compared with the previous year were primarily attributed to timing differences in customer deliveries rather than demand weakness, while profitability margins remained robust.
Financial Highlights:
- Revenue from Operations: ₹4,182 million (↓22.6% YoY | ↓31.5% QoQ)
- Total Revenue: ₹4,431 million (↓21.3% YoY | ↓33.1% QoQ)
- EBITDA: ₹1,755 million (↓18.1% YoY | ↓44.9% QoQ)
- EBITDA Margin: 39.6%
- Profit Before Tax (PBT): ₹1,446 million (↓22.4% YoY | ↓48.0% QoQ)
- Profit After Tax (PAT): ₹1,199 million (↓11.7% YoY | ↓36.8% QoQ)
- PAT Margin: 27.1%
- CRDMO Revenue: ₹3,408 million (↓24.7% YoY)
- Specialty Ingredients Revenue: ₹774 million (↓11.5% YoY)
- Other Income: ₹249 million (↑9.2% YoY)
Highlight:
- EBITDA Margin: 39.6%, despite lower revenues during the quarter.
What Happened ?
Anthem Biosciences announced its revised press release for the unaudited consolidated financial results for Q1 FY27. The company reported lower revenues and profits compared with the corresponding quarter last year, primarily due to the timing of customer deliveries. Despite the revenue decline, the company sustained industry-leading profitability margins through operational efficiency, cost optimization, and productivity improvements.
key details
Business & Operational Highlights:
- Consolidated revenue from operations stood at ₹4,182 million.
- The CRDMO business contributed ₹3,408 million in revenue.
- Specialty Ingredients business generated ₹774 million in revenue.
- EBITDA remained at ₹1,755 million, delivering a margin of 39.6%.
- PAT stood at ₹1,199 million, translating into a 27.1% PAT margin.
- Other income increased to ₹249 million, supported by forex gains, RoDTEP incentives, and financial income.
- The company announced an earnings call on 22 July 2026 to discuss quarterly performance with investors.
Note: Management stated that the quarterly decline reflects delivery scheduling by key customers rather than a slowdown in underlying demand and expects stronger execution during the second half of FY27.
Risk Analysis
Summary:
- The decline in revenue and earnings was linked to shipment timing rather than demand destruction. However, customer concentration and execution timing continue to influence quarterly performance.
Key Risks:
- Revenue remains sensitive to the timing of deliveries from key customers.
- Quarterly earnings may fluctuate due to the project-based nature of the CRDMO business.
- Dependence on customer execution schedules could impact near-term financial performance.
- Foreign exchange movements may affect reported profitability.
Worst Case:
- If customer delivery schedules continue to shift or demand weakens unexpectedly, revenue recovery could be delayed, affecting earnings growth despite the company’s strong margin profile.
Risk Level: Medium
Company Commentary
- Management attributed the quarter’s performance to timing shifts in deliveries to key customers.
- The company stated that underlying customer demand remains strong.
- Anthem expects a higher concentration of scheduled deliveries in the latter half of FY27.
- Management reaffirmed its commitment to long-term revenue growth aligned with historical performance.
- Continued focus on cost efficiency, yield optimization, and employee productivity helped sustain strong EBITDA and PAT margins.
Official Exchange Filing: Anthem Biosciences Limited
